Intellia Therapeutics (NTLA) Operating Leases (2019 - 2026)

Intellia Therapeutics (NTLA) has 8 years of Operating Leases data on file, last reported at $61.4 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 23.72% year-over-year to $61.4 million in Q1 2026; TTM through Mar 2026 was $61.4 million, a 23.72% decrease from a year earlier, with the FY2025 full-year figure at $66.8 million, down 64.81% from the prior year.
• Operating Leases for Q1 2026 stood at $61.4 million, down from $66.8 million in the prior quarter.
• Over the last five years, Operating Leases for NTLA reached as high as $190.0 million in Q4 2024 and fell as low as $60.0 million in Q2 2022.
• Historically, Operating Leases has averaged $90.6 million across 5 years, with a median of $84.1 million in 2022.
• Across the five-year window, Operating Leases soared 96.34% in 2024 and sank 64.81% in 2025, its largest moves.
• Year by year, Operating Leases stood at $114.0 million in 2022, then fell by 15.15% to $96.7 million in 2023, then jumped by 96.34% to $190.0 million in 2024, then sank by 64.81% to $66.8 million in 2025, then slipped by 8.16% to $61.4 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $61.4 million in Q1 2026, $66.8 million in Q4 2025, and $70.6 million in Q3 2025.